CONCORDANCE OF THE FDA-APPROVED COMPANION DIAGNOSTIC AND A NEXT-GENERATION SEQUENCING ASSAY KIT FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN OVARIAN CANCER

被引：0

作者：

Weichert, W. ^{[1
]}

Qiu, P. ^{[2
]}

Lunceford, J. ^{[2
]}

Wehn, A. ^{[2
]}

Yarunin, A. ^{[3
]}

Marton, M. ^{[2
]}

机构：

[1] Tech Univ Munich, Inst Pathol, Munich, Germany

[2] Merck & Co Inc, Kenilworth, NJ USA

[3] AstraZeneca, Alderley Pk, England

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷

关键词：

D O I：

10.1136/ijgc-2021-ESGO.665

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

978

引用

页码：A375 / A375

页数：1

共 41 条

[1] Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer
Wehn, Amy K.
Qiu, Ping
Lunceford, Jared
Yarunin, Alexander
Cristescu, Razvan
Liu, Li
Roessler, Kyria
Bilke, Sven
Timms, Kirsten M.
Weichert, Wilko
Marton, Matthew J.
GYNECOLOGIC ONCOLOGY, 2024, 184 : 67 - 73
[2] Assessing homologous recombination deficiency (HRD) in ovarian cancer: Optimizing concordance of the regulatory-approved companion diagnostic and a next-generation sequencing (NGS) assay kit.
Weichert, Wilko
Qiu, Ping
Lunceford, Jared
Wehn, Amy
Yarunin, Alexander
Cristescu, Razvan
Liu, Li
Roessler, Kyria
Timms, Kirsten
Marton, Matthew John
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17571 - E17571
[3] Analytical Performance of a Next-Generation Sequencing (NGS) Assay Kit for Assessing Homologous Recombination Deficiency (HRD) from Solid Tumor Samples
Liu, L.
Roessler, K.
Bilke, S.
Ding, Y.
Erlandson, D.
Fu, Y.
Hariharan, B.
Katz, S.
Lee, J.
Schulman, C.
Song, F.
Vijayaraghavan, R.
Wenz, P.
Xia, E.
Yan, H.
Zhu, Y.
Zhao, C.
Dockter, J.
Pawlowski, T.
Day, J.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : S91 - S91
[4] Analytical performance of a next-generation sequencing (NGS) assay kit for assessing homologous recombination deficiency (HRD) from solid tumor samples
Liu, L.
Roessler, K.
Bilke, S.
Ding, Y.
Erlandson, D.
Fu, Y.
Hariharan, B.
Katz, S.
Lee, J.
Schulman, C.
Song, F.
Vijayaraghavan, R.
Wenz, P.
Xia, E.
Yan, H.
Zhu, Y.
Zhao, C.
Dockter, J.
Pawlowski, T.
Day, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S969 - S969
[5] Next-generation sequencing-based analysis of homologous recombination repair gene variant in ovarian cancer
Song, Yaolin
Ran, Wenwen
Jia, Huiqing
Yao, Qin
Li, Guangqi
Chen, Yang
Wang, Xiaonan
Xiao, Yujing
Sun, Mengqi
Lu, Xiao
Xing, Xiaoming
HELIYON, 2024, 10 (02)
[6] Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma
Liu, Hangqi
Zhang, Zhiwen
Chen, Longyun
Pang, Junyi
Wu, Huanwen
Liang, Zhiyong
FRONTIERS IN ONCOLOGY, 2022, 11
[7] Next-Generation Sequencing as a Diagnostic Tool for Hereditary Breast and Ovarian Cancer
Dai, Z.
Bean, L. J.
Collins, C.
Askree, S. H.
Alexander, J. J.
Hegde, M.
Tanner, A.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 761 - 761
[8] Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test
Razvan Cristescu
Xiao Qiao Liu
Gladys Arreaza
Cai Chen
Andrew Albright
Ping Qiu
Matthew J. Marton
BMC Cancer, 22
[9] Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
Kim, S.
Han, M-R.
Oh, E-Y.
Choi, Y. J.
Bak, S.
ANNALS OF ONCOLOGY, 2023, 34 : S1179 - S1179
[10] Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
Choi, Boram
Choi, Youn Jin
CANCER RESEARCH, 2024, 84 (06)

← 1 2 3 4 5 →